Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials

Area of Science:

• Cardiovascular Imaging
• Medical Diagnostics
• Genetics and Hereditary Diseases

Background:

• Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol and premature cardiovascular disease.
• Aggressive statin therapy is standard for FH, but residual risk persists, necessitating advanced risk assessment.
• Computed tomographic angiography (CTA) offers detailed visualization of coronary anatomy and atherosclerotic plaque.

Purpose of the Study:

• To review current clinical applications of CTA in familial hypercholesterolemia.
• To summarize recent CTA research findings in high-risk cardiovascular populations.
• To explore the role of CTA in identifying subclinical atherosclerosis and guiding treatment in FH.

Main Methods:

• Review of existing literature on CTA in familial hypercholesterolemia.
• Analysis of data from the COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry.
• Correlation of CTA findings (plaque burden, stenosis) with clinical outcomes (all-cause mortality).

Main Results:

• Significant coronary artery disease (CAD), including nonobstructive plaque, is prevalent in asymptomatic FH patients on long-term statin therapy.
• The presence and extent of nonobstructive CAD visualized by CTA are associated with increased all-cause mortality.
• Statin therapy was linked to reduced mortality in patients with atherosclerotic plaque but not in those with normal coronary arteries on CTA.

Conclusions:

• CTA imaging demonstrates that substantial plaque burden can exist in FH patients despite aggressive statin treatment.
• Nonobstructive CAD identified by CTA is a predictor of mortality, and statins may prolong survival in these individuals.
• Further clinical trials utilizing CTA are essential for refining CAD detection and developing personalized treatment strategies for familial hypercholesterolemia.